| 000 | 02027cam a2200337 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223031736.0 | ||
| 008 | 170619s2016 ua dh f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aPh.D | ||
| 099 | _aCai01.08.08.Ph.D.2016.Ka.D | ||
| 100 | 0 | _aKarim Aboubakr Mohamed Mohamed Soliman | |
| 245 | 1 | 0 |
_aDesign, preparation and evaluation of a certain phosphodiesterase (PDE5) inhibitor in solid dosage forms / _cKarim Aboubakr Mohamed Mohamed Soliman ; Supervised Mahmoud Mohammed Ghorab , Howida Kamal Ibrahim |
| 246 | 1 | 5 | _aتصميم وتحضير وتقييم لعقار مثبط لانزيم الفوسفوديستريس في صورة مستحضرات صيدلية صلبة |
| 260 |
_aCairo : _bKarim Aboubakr Mohamed Mohamed Soliman , _c2016 |
||
| 300 |
_a288 P. : _bcharts , facsimiles ; _c30cm |
||
| 502 | _aThesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics | ||
| 520 | _avanafil is an inhibitor of phosphodiesterase enzyme type 5 (PDE5). It was approved for treatment of erectile dysfunction by US Food and Drug Administration on April 2012, and by European Medicines Agency on June 2013. It is characterized by its rapid onset of action and it exhibits visual side effects to a lesser extent than other PDE5 inhibitors. It is poorly soluble in water and has relatively low bioavailability of 38%{u2013}41%. Its oral bioavailability could be increased by improving its aqueous solubility using different techniques. These include nanocrystallization, inclusion complexation and nanoemulsification | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aCanines | |
| 653 | 4 | _aMaxillary and Mandibular | |
| 653 | 4 | _aPermanent Mandibular Incisors | |
| 700 | 0 |
_aHowida Kamal Ibrahim , _eSupervisor |
|
| 700 | 0 |
_aMahmoud Mohammed Ghorab , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aShimaa _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c61335 _d61335 |
||